• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - HLTHSE
Tag:

HLTHSE

Business

Roche Challenges Illumina with New Axelios Gene Sequencer

by Chief Editor June 29, 2026
written by Chief Editor

Roche has launched its Axelios gene sequencer, a new platform designed to perform large-scale DNA and RNA analysis, marking the company’s attempt to compete with industry leader Illumina. Roche aims to sell about 100 machines within the first year, targeting academic and research institutions to build a foundation for long-term growth in the $7.3 billion sequencing market.

How does the Axelios platform differ from existing technology?

Unlike traditional short-read sequencing systems, the Axelios platform converts genetic material into longer molecules. These molecules are processed through tiny pores on a reusable chip to generate data in near real time. By focusing on this method, Roche aims to support applications ranging from disease research to drug development.

To ensure adoption, Roche has secured partnerships for data analysis with 10x Genomics and Google DeepVariant. Early validation for the platform has been provided by the Broad Clinical Labs and the Hartwig Medical Foundation.

Did you know?

Roche’s launch comes more than a decade after the group’s failed $6.8 billion hostile bid to acquire Illumina.

What is the market outlook for Roche’s new sequencer?

Analysts anticipate a gradual push for market share rather than a rapid disruption. Illumina currently holds approximately 70% of the next-generation sequencing (NGS) market, according to industry estimates.

What is the market outlook for Roche’s new sequencer?

Vontobel analyst Stefan Schneider stated that Roche’s target of 100 machines in the first year is achievable due to the company’s commercial scale. However, Schneider noted that diagnostic product launches often experience slower adoption rates compared to medicines because of institutional tender processes.

How do pricing models affect laboratory adoption?

Roche has priced the Axelios instrument at $750,000 in the United States. This is competitive when compared to Illumina’s NovaSeq X machines, which list between $985,000 and $1.25 million.

How do pricing models affect laboratory adoption?

Analysts note the upfront cost of the instrument is secondary to the recurring cost of supplies needed to run it, such as chemical reagents. These ongoing expenses can add up to millions of dollars over the lifespan of the machine.

Pro Tip:

When evaluating sequencing platforms, labs should prioritize the “total cost of ownership” rather than the initial hardware price, as reagent consumption often dictates the long-term budget impact of the technology.

Frequently Asked Questions

Who is the primary target audience for the Axelios sequencer?
The initial launch is restricted to academic and research-focused facilities.
What is Roche’s long-term sales goal for this platform?
The company intends to develop the Axelios into a blockbuster franchise, with the goal of generating over 1 billion Swiss francs ($1.1 billion) in annual sales over the long term.
Does the Axelios sequence DNA or RNA?
The platform is designed to handle both DNA and ribonucleic acid (RNA) by converting them into longer molecules for easier reading.

Are you involved in genomic research or laboratory procurement? Share your thoughts on the impact of new sequencing platforms in the comments below, or subscribe to our newsletter for the latest updates on biotech industry developments.

June 29, 2026 0 comments
0 FacebookTwitterPinterestEmail
Business

Merck to Acquire Bio-Techne in $11 Billion Life Sciences Deal

by Chief Editor June 25, 2026
written by Chief Editor

Merck KGaA has announced an $11.3 billion agreement to acquire U.S.-based Bio-Techne, marking the German pharmaceutical giant’s largest acquisition since 2014. The deal, which offers $73 per share—a 24% premium over the closing price on Wednesday—is designed to bolster Merck’s life sciences division by integrating Bio-Techne’s extensive portfolio of research reagents, proteins, and analytical instruments into its global supply chain.

Why Merck is targeting the research tools market

Merck is betting that the demand for sophisticated drug research and manufacturing tools will remain a primary growth engine for its life sciences unit. According to Merck Life Science CEO Jean-Charles Wirth, the acquisition provides access to a $27 billion market opportunity. By adding Bio-Techne’s catalog of 6,000 proteins and 425,000 antibodies, Merck aims to solidify its position in advanced biological research and cell and gene therapy development.

Did you know? This transaction is Merck’s largest since its $17 billion purchase of Sigma-Aldrich in 2014, a deal that fundamentally reshaped the company’s research tools division.

How market valuations influenced the deal

Timing played a critical role in the acquisition, as shifting market conditions allowed Merck to secure the deal at a more favorable valuation than in previous years. Merck KGaA CEO Kai Beckmann noted to reporters that the current price point “wasn’t possible two years ago,” when demand for research tools reached an all-time high during the COVID-19 pandemic. As valuations for biotech and research supply firms have cooled, industry leaders are finding new opportunities to expand their footprints.

How market valuations influenced the deal

Pro Tip: When evaluating pharmaceutical M&A, look beyond the share premium. Analysts at Leerink, including Puneet Souda, emphasize that the strategic fit of the assets—specifically their long-term potential in high-growth research areas—often outweighs short-term market pressures.

What happens after the acquisition closes?

Merck anticipates the deal will close between late 2026 and early 2027, subject to regulatory approval. Once finalized, the company expects to generate approximately 140 million euros in cost savings by the third year. The acquisition will be funded through a mix of cash and debt, utilizing the company’s existing cash reserves, which stood at roughly 2.74 billion euros as of March 31.

Frequently Asked Questions

How much is Merck paying for Bio-Techne?

Merck has offered $73 per share, valuing the company at $11.3 billion.

Micron Soars, Dell Falls, Bio-Techne Drops After Merck KGaA Secures $11.3 Billion Purchase |…

When is the deal expected to close?

The companies expect the transaction to close by late 2026 or early 2027.

What specific products does Bio-Techne provide?

Bio-Techne supplies essential tools for drug development, including research reagents, proteins, antibodies, and analytical instruments.

Are there expected regulatory hurdles?

Some analysts, as reported by Reuters, suggest that the deal is a strong strategic fit and do not currently anticipate significant regulatory obstacles.


Are you tracking the latest shifts in biotech infrastructure? Sign up for our weekly industry newsletter to receive updates on major pharmaceutical acquisitions and emerging trends in life sciences.

June 25, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

FDA Approves Over-the-Counter Screwworm Treatment for Pets

by Chief Editor June 11, 2026
written by Chief Editor

The U.S. Food and Drug Administration (FDA) has authorized the emergency use of generic nitenpyram tablets to treat New World screwworm infestations in cats and dogs. This regulatory action follows the first domestic detection of the parasite in over 60 years, with confirmed cases in cattle, a goat, and a dog across Texas and New Mexico.

What is the New World Screwworm?

The New World screwworm (Cochliomyia hominivorax) is a parasitic fly whose larvae feed on the living tissue of warm-blooded animals. According to the FDA, the parasite enters an animal’s body through open wounds, where it burrows into the flesh. If left untreated, these infestations can cause severe tissue damage and systemic infection.

View this post on Instagram about Texas and New Mexico, United States
From Instagram — related to Texas and New Mexico, United States
Did you know?

The New World screwworm was largely eradicated in the United States decades ago through a sterile insect technique program. The recent emergence in Texas and New Mexico marks the first domestic presence of the parasite in more than six decades.

How does the FDA-authorized treatment work?

Nitenpyram is a fast-acting oral medication now cleared under an emergency pathway to address current infestation risks. The FDA states that the drug can be administered to pets weighing at least two pounds that are at least four weeks old. Clinical evidence suggests the treatment kills most larvae within hours of the initial dose.

Veterinary guidance remains critical, however. According to the FDA, a second dose should be administered six hours after the first. The agency warns that nitenpyram does not provide residual protection against reinfestation, meaning veterinarians must often manually remove remaining larvae and provide standard wound care to ensure full recovery.

What are the risks and precautions for pet owners?

While the FDA maintains that the benefits of the treatment outweigh the potential risks, the drug is not a standalone solution for severe cases. Officials at the FDA emphasize that animals recently present in affected regions of Texas and New Mexico are at higher vulnerability, though the general risk to pets nationwide remains low.

FDA Direct — Understanding New World Screwworm w/ FDA's Vet Expert
Pro Tip:

If you suspect your pet has been exposed to the New World screwworm, contact your veterinarian immediately. Do not attempt to treat deep, burrowing wounds at home without professional medical oversight.

Future trends in veterinary parasite control

The FDA’s move to use an emergency pathway for a generic animal drug signals a shift in how federal agencies address localized disease outbreaks. By prioritizing affordable, accessible treatments, the government aims to prevent the spread of the screwworm before it reaches broader livestock populations. This strategy mirrors historical efforts to contain agricultural threats through rapid regulatory approval of existing, proven pharmaceuticals.

Future trends in veterinary parasite control

Frequently Asked Questions

  • Is this treatment available over-the-counter? Yes, the FDA authorized this generic tablet for emergency use to ensure pet owners have immediate access.
  • Can I use this for all pets? The authorization is specific to dogs and cats weighing at least two pounds and aged four weeks or older.
  • Does nitenpyram prevent future infestations? No. The FDA notes that the drug does not protect against reinfestation and should be used alongside professional veterinary care.
  • Where have the recent cases occurred? U.S. officials confirmed cases in Texas and New Mexico.

Have you checked your pet for unusual wounds recently? Share your experiences in the comments below or subscribe to our health newsletter for the latest updates on veterinary medical breakthroughs.

June 11, 2026 0 comments
0 FacebookTwitterPinterestEmail

Recent Posts

  • Police Block TTAP Delegation From Joining AJK Sit-In

    June 29, 2026
  • Lecanemab: Modest Alzheimer’s Benefits vs. High Risks

    June 29, 2026
  • Webb Telescope Maps Millions of Stars in Messier 82

    June 29, 2026
  • Hundreds of Fake Rental Contracts Used to Exploit Immigrants in Porto

    June 29, 2026
  • Rockstar’s GTA VI kills physical media-digital-only launch sparks backlash

    June 29, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

© 2026 Newsy Today. All rights reserved.
For contact, advertising, copyright, issues email: [email protected]


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World